Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.

Rhea-AI Summary

Abeona Therapeutics (Nasdaq: ABEO) granted equity awards to new non-executive employees under Nasdaq Listing Rule 5635(c)(4) as a material inducement to employment.

On June 30, 2026, five hires received restricted stock awards totaling up to 9,000 shares, vesting in three equal annual installments over three years, subject to continued employment.

Argus Jul 1 session

-2.10% close to close Open Argus

Details

News Market Reaction – ABEO

On Jul 1, the day this news came out, ABEO closed 2.10% below the previous close.

Data tracked by StockTitan Argus for the Jul 1 session.

Key Figures

Restricted shares granted: 9,000 shares New hires receiving awards: 5 individuals Vesting schedule: One-third per year

Restricted shares granted

9,000 shares

Aggregate inducement awards to five new non-executive employees

New hires receiving awards

5 individuals

Non-executive employees granted inducement restricted stock

Vesting schedule

One-third per year

Restricted stock vests annually over three years from Grant Date

Historical Context

5 past events · Latest: Jun 01

5 events

1. Jun 01

   Employee inducement grants

   24h Move

   -2.6%

   New-hire inducement restricted stock awards granted under Nasdaq Rule 5635(c)(4).

2. May 26

   Investor conferences

   24h Move

   +0.9%

   Management participation in two June 2026 healthcare investor conferences and meetings.

3. May 13

   Quarterly earnings

   24h Move

   +0.5%

   Q1 2026 results with higher ZEVASKYN-driven revenue and strong cash balance.

4. May 11

   Commercial expansion

   24h Move

   -0.7%

   CHOP activated as sixth Qualified Treatment Center for ZEVASKYN, expanding access.

5. May 04

   Earnings date set

   24h Move

   +9.6%

   Announcement of date and details for upcoming Q1 2026 earnings call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4), restricted stock

2 terms

nasdaq listing rule 5635(c)(4) regulatory

"The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

restricted stock financial

"granted restricted stock equity awards as a material inducement to employment"

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CLEVELAND, July 01, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4).

On June 30, 2026, the Compensation Committee of Abeona’s Board of Directors granted restricted stock equity awards as a material inducement to employment to five individuals hired by Abeona, which equity awards relate to, in the aggregate, up to 9,000 restricted shares of Abeona common stock. One-third of the shares subject to such restricted stock awards is scheduled to vest yearly on each anniversary of the Grant Date, such that the shares subject to such restricted stock awards granted to each employee are scheduled to be fully vested on the third anniversary of the Grant Date, in each case, subject to each employee’s continued employment with Abeona on the applicable vesting dates.

About Abeona Therapeutics

Abeona Therapeutics Inc. is a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases. Abeona’s ZEVASKYN^® (prademagene zamikeracel) is the first and only autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The Company’s fully integrated cell and gene therapy cGMP manufacturing facility in Cleveland, Ohio serves as the manufacturing site for ZEVASKYN commercial production. The Company’s development portfolio features ABO-701 (PSMA-SIR-T™), a potentially first-in-class engineered T-cell therapy targeting PSMA, engineered to overcome the core failures of cell therapies in solid tumors. For more information, visit www.abeonatherapeutics.com.

ZEVASKYN^®, Abeona Assist™, Abeona Therapeutics^®, and their related logos are trademarks of Abeona Therapeutics Inc.

Contacts:

Investor and Media
Greg Gin
VP, Investor Relations and Corporate Communications
Abeona Therapeutics
ir@abeonatherapeutics.com

Investor
Lee M. Stern
Meru Advisors
lstern@meruadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What employee inducement grants did Abeona Therapeutics (ABEO) announce on July 1, 2026?

Abeona Therapeutics announced restricted stock equity awards for five new non-executive employees. According to Abeona, these inducement grants cover up to 9,000 restricted shares of common stock and were approved as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

How many Abeona Therapeutics (ABEO) shares are included in the July 2026 inducement grants?

The July 2026 inducement grants relate to an aggregate of up to 9,000 restricted shares. According to Abeona, these shares of common stock were granted to five new non-executive employees as equity awards approved by the board’s Compensation Committee on June 30, 2026.

What is the vesting schedule for Abeona Therapeutics (ABEO) July 2026 restricted stock awards?

The restricted stock awards vest over three years in equal parts. According to Abeona, one-third of each employee’s shares is scheduled to vest annually on each grant-date anniversary, with full vesting on the third anniversary, subject to the employee’s continued employment.

Who received the July 2026 inducement equity awards from Abeona Therapeutics (ABEO)?

Five new non-executive employees received the July 2026 inducement equity awards. According to Abeona, these individuals were granted restricted stock as a material inducement to join the company, with awards relating in total to up to 9,000 restricted shares of common stock.

Why did Abeona Therapeutics (ABEO) use Nasdaq Listing Rule 5635(c)(4) for its July 2026 grants?

Abeona used Nasdaq Listing Rule 5635(c)(4) to grant equity awards as a material inducement to employment. According to Abeona, the restricted stock awards to five new non-executive employees were approved in accordance with this specific Nasdaq listing rule.

What conditions affect vesting of Abeona Therapeutics (ABEO) July 2026 restricted stock grants?

Vesting depends on each employee’s continued employment with Abeona. According to Abeona, the restricted shares vest one-third yearly on each grant-date anniversary, and are scheduled to be fully vested on the third anniversary only if employment continues on each vesting date.